Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.36B P/E - EPS this Y -48.00% Ern Qtrly Grth -
Income -252.43M Forward P/E -8.38 EPS next Y 40.50% 50D Avg Chg -
Sales 799.6M PEG -0.29 EPS past 5Y - 200D Avg Chg 16.00%
Dividend N/A Price/Book 0.88 EPS next 5Y 12.00% 52W High Chg -36.00%
Recommedations 1.50 Quick Ratio 0.95 Shares Outstanding 696.99M 52W Low Chg 76.00%
Insider Own 52.41% ROA -6.01% Shares Float 331.04M Beta 1.81
Inst Own 23.62% ROE -18.00% Shares Shorted/Prior 86.57M/93.61M Price 1.76
Gross Margin 22.76% Profit Margin -31.57% Avg. Volume 3,801,127 Target Price 4.25
Oper. Margin -41.15% Earnings Date Aug 1 Volume 2,222,674 Change -3.30%
About Opko Health, Inc.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.

Opko Health, Inc. News
05/09/24 OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y
05/08/24 OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
05/08/24 Q1 2024 OPKO Health Inc Earnings Call
05/08/24 OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ...
05/07/24 Opko Health (OPK) Q1 2024 Earnings Call Transcript
05/07/24 OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
05/07/24 OPKO Health Inc (OPK) Q1 2024 Earnings: Misses Revenue and Earnings Estimates
05/07/24 OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
05/07/24 OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
05/03/24 OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
04/01/24 OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
04/01/24 Labcorp (LH) to Boost Clinical Diagnostics With New Deal
03/28/24 Labcorp inks $237.5M buyout of Opko’s reproductive, women’s health testing assets
03/28/24 Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
03/25/24 OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
03/20/24 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
03/05/24 AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
03/01/24 Analysts Have Lowered Expectations For OPKO Health, Inc. (NASDAQ:OPK) After Its Latest Results
02/29/24 OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript
02/29/24 OPKO Health Full Year 2023 Earnings: EPS Beats Expectations
OPK Chatroom

User Image wycliff Posted - 5 hours ago

$OPK https://www.benzinga.com/trading-ideas/long-ideas/24/05/38917316/3-5m-bet-on-this-healthcare-stock-check-out-these-3-penny-stocks-insiders-are-aggressive

User Image tymtested Posted - 7 hours ago

$OPK Acromegaly companies working in the treatment market are OPKO Health, Amolyt Pharma, Debiopharm International, Glytech, Antisense Therapeutics, Crinetics Pharmaceuticals Inc., Camurus AB, and others, are developing therapies for the Acromegaly treatment

User Image tymtested Posted - 7 hours ago

$OPK Emerging players, fueled by technological advancements and strategic collaborations, are also making significant strides in the market. Companies like Cytiva, AnteoTech, and OPKO Health are gaining traction with their innovative paper-based diagnostic solutions, catering to the evolving needs of healthcare providers and patients worldwide.

User Image wycliff Posted - 10 hours ago

$OPK http://redirect.viglink.com/?key=71fe2139a887ad501313cd8cce3053c5&subId=6175870&u=https%3A//finance.yahoo.com/news/nextplat-reports-record-consolidated-q1-140900152.html

User Image tymtested Posted - 11 hours ago

$OPK

User Image tymtested Posted - 12 hours ago

$OPK

User Image tymtested Posted - 12 hours ago

$OPK

User Image tradertrash Posted - 15 hours ago

$OPK fk retail...rinse repeat

User Image tradertrash Posted - 15 hours ago

$OPK creating value for mgt is what There all about

User Image tradertrash Posted - 16 hours ago

$OPK the curse of r&d eating sh profits, need to pharm it all out to partners imo, they never deliver sh*t, just take

User Image NEWBIGTECH Posted - 1 day ago

$OPK

User Image tymtested Posted - 1 day ago

$OPK the initial strategy was for BRL to be a cash generator for R&D. Didn’t happen. So now Frost is getting rid of the cash burning operations. He can see cash inflows from Ngenla and other parts of the business. Stock is going up.

User Image DoublingDollars Posted - 2 days ago

$OPK Going to hit $2.20's before the summer is over. Frost selling some more of the lab I think.

User Image tymtested Posted - 2 days ago

$OPK frost’s purchase of a peculiar number of shares on Friday 163997 was a secret signal to investors who bought over 13,000 call options on Friday as well. Stock is about to explode..imho.

User Image NEWBIGTECH Posted - 3 days ago

$OPK OPK Stock 12 Month Forecast Based on 3 Wall Street analysts offering 12 month price targets for Opko Health in the last 3 months. The average price target is $3.17 with a high forecast of $5.00 and a low forecast of $1.50

User Image tymtested Posted - 3 days ago

$OPK why does Frost keep buying OPKO shares?

User Image wycliff Posted - 3 days ago

$OPK https://ir.stockpr.com/opko/sec-filings-email/content/0000950170-24-061910/ownership.html

User Image Aopwarrior Posted - 3 days ago

$OPK so whats the story here?

User Image TeresaTrades Posted - 3 days ago

Heavy options volume $FTDR $FFIE $ASTS $OPK $PTEN

User Image tymtested Posted - 3 days ago

$OPK Frost will never let OPKO fail ultimately

User Image Hokuzen Posted - 3 days ago

$OPK buyout news

User Image StockTAguru Posted - 3 days ago

$OPK breaking 1.43, then 1.66

User Image BigTB Posted - 3 days ago

$OPK Shorts get ready! Going higher. Much!

User Image zaza1 Posted - 3 days ago

$OPK is looking like our day

User Image tradertrash Posted - 3 days ago

$OPK news?

User Image tradertrash Posted - 3 days ago

$OPK volume spike to start the day?

User Image JonETrades Posted - 3 days ago

$OPK 2C 09/20 $112k

User Image Ironfighter Posted - 3 days ago

$OPK when was frosts last stock purchase?

User Image zaza1 Posted - 4 days ago

$OPK Frosty doesn't buy for weeks Something is coming..

User Image tymtested Posted - 4 days ago

$OPK WGS has added OVER $50,000,000 to OPKO's value in the second quarter alone!! this is not included in the guidance nor has the market recognized this yet!!

Analyst Ratings
HC Wainwright & Co. Buy May 8, 24
HC Wainwright & Co. Buy Apr 3, 24
Barrington Research Outperform Apr 1, 24
Piper Sandler Overweight Apr 1, 24
HC Wainwright & Co. Buy Feb 28, 24
Barrington Research Outperform Feb 28, 24
HC Wainwright & Co. Buy Aug 7, 23
Barrington Research Outperform Jun 29, 23
HC Wainwright & Co. Buy May 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
KRASNO RICHARD M Director Director Jan 29 Buy 0.9946 30,000 29,838 103,333 01/29/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 19 Buy 0.9773 500,000 488,650 205,868,225 01/19/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 18 Buy 0.9655 400,000 386,200 205,368,225 01/18/24
HSIAO JANE PH D Vice Chairman & CTO Vice Chairman & CTO Jan 17 Buy 0.95 150,000 142,500 27,999,880 01/17/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 16 Buy 0.9543 1,000,000 954,300 204,968,225 01/16/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 11 Buy 0.9391 511,531 480,379 203,968,225 01/11/24
Nabel Gary J. Chief Innovation Off.. Chief Innovation Officer Jan 08 Buy 0.92 216,184 198,889 107,489 01/10/24
HSIAO JANE PH D Vice Chairman & CTO Vice Chairman & CTO Jan 04 Buy 0.8726 150,010 130,899 27,849,880 01/08/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 04 Buy 0.8964 1,500,000 1,344,600 203,456,694 01/08/24
Zerhouni Elias A. Vice Chairman and Pr.. Vice Chairman and President Jan 05 Buy 0.91 550,300 500,773 20,327,814 01/05/24
PFENNIGER RICHARD C JR Director Director Jan 05 Buy 0.94 25,000 23,500 325,000 01/05/24
Rubin Steven D Executive VP-Adminis.. Executive VP-Administration Nov 10 Buy 1.30 10,000 13,000 6,177,732 11/13/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 17 Buy 1.76 100,000 176,000 200,956,694 08/18/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 14 Buy 1.75 75,000 131,250 200,856,694 08/15/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 09 Buy 1.82 100,000 182,000 200,781,694 08/10/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 07 Buy 1.84 650,000 1,196,000 200,681,694 08/08/23
Nabel Gary J. Chief Innovation Off.. Chief Innovation Officer May 05 Buy 1.82 460,245 837,646 242,747 05/08/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Mar 22 Buy 1.32 200,000 264,000 200,031,694 03/23/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Mar 08 Buy 1.2 1,000,000 1,200,000 199,831,694 03/09/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Nov 22 Buy 1.49 300,000 447,000 198,831,694 11/23/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Nov 09 Buy 1.6 200,000 320,000 198,531,694 11/10/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Oct 27 Buy 1.82 100,000 182,000 198,331,694 10/28/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Oct 19 Buy 1.71 100,000 171,000 198,231,694 10/20/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 26 Buy 1.8 50,000 90,000 197,756,694 09/27/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 23 Buy 1.85 50,000 92,500 197,706,694 09/26/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 22 Buy 1.9 50,000 95,000 197,656,694 09/23/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 21 Buy 1.91 50,000 95,500 197,606,694 09/22/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 20 Buy 1.94 50,000 97,000 197,556,694 09/21/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 19 Buy 1.97 50,000 98,500 197,506,694 09/20/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 02 Buy 2.14 100,000 214,000 197,256,694 09/06/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 17 Buy 2.54 200,000 508,000 197,156,694 08/18/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 05 Buy 2.28 350,000 798,000 196,956,694 08/08/22
Nabel Gary J. Chief Innovation Off.. Chief Innovation Officer Jun 22 Buy 2.49 240,000 597,600 80,000 06/24/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 21 Buy 2.4 200,000 480,000 196,606,694 06/22/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 16 Buy 2.32 100,000 232,000 196,406,694 06/17/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 13 Buy 2.36 100,000 236,000 196,306,694 06/14/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 06 Buy 2.8 100,000 280,000 196,206,694 06/07/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 01 Buy 2.97 50,000 148,500 196,106,694 06/02/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 31 Buy 3.03 50,000 151,500 196,056,694 06/01/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 25 Buy 2.98 50,000 149,000 196,006,694 05/26/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 18 Buy 2.88 50,000 144,000 195,956,694 05/19/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 16 Buy 2.98 150,000 447,000 195,906,694 05/17/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 13 Buy 3 200,000 600,000 195,756,694 05/16/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 11 Buy 2.831 400,000 1,132,400 195,556,694 05/12/22
Zerhouni Elias A. Vice Chairman and Pr.. Vice Chairman and President May 09 Buy 2.7946 89,600 250,396 89,600 05/11/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 10 Buy 2.7839 400,000 1,113,560 195,156,694 05/11/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Mar 14 Buy 3.04 35,000 106,400 194,756,694 03/15/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Mar 11 Buy 3.13 100,000 313,000 194,721,694 03/14/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Feb 28 Buy 3.1 100,000 310,000 194,621,694 03/01/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Feb 25 Buy 3.0871 750,000 2,315,325 194,521,694 02/28/22